RBC Lifts Price Target on V2X to $60 From $55, Says 'Strong' Q4 Revenue 'Should Support Confidence' in 2023 Growth, Keeps Outperform Rating
RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confidence on Patents, Keeps Outperform Rating, Speculative Risk Qualifier
No Data
No Data